Gasoyan added that, in this large observational study of patients who discontinued semaglutide or tirzepatide, reinitiation of the original medication or receipt of alternative obesity treatment was common, which may explain why they regained less weight than patients in randomized trials. Additionally, previous research suggests that GLP-1 drug discontinuation often occurs for practical reasons rather than lack of effectiveness
M.MarsheV
By setting realistic expectations, citing evidence responsibly, and engaging in shared decisionmaking, clinicians can navigate these conversations with confidence
Orandi , MD, PhD , can be reached at [email protected].
Importantly, emerging evidence suggests that combination therapy with GLP-1 RAs and SGLT2is may provide synergistic benefits, producing greater reductions in body weight, glycated hemoglobin (HbA1c), and potentially liver-related endpoints compared with either therapy alone
The connection between tirzepatide and dry mouth is well-documented by users, even though it does not appear prominently in clinical trial data
